Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Olivier Le Rouzic, Muriel Pichavant, Emilie Frealle, Antoine Guillon, Mustapha Si-Tahar, Philippe Gosset. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016

Member's Comments

No comment yet.

Related content which might interest you: T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease Source: Eur Respir J 2007; 30: 383-390 Year: 2007 The roles of Th2 cytokines and their signaling pathways in the pathogenesis of non-eosinophilic asthma enhanced by dsRNA Source: Annual Congress 2006 - Immunological mechanisms in cell recruitment to the lungs Year: 2006 Evidence for differential roles of Th1 and Th17 cytokines in the pathogenesis of COPD Source: Annual Congress 2010 - Pathology and immunology of COPD Year: 2010 IL-17 and Th17-cells as markers of disease progression in pediatric allergic diseases. A therapeutic approach in an "in vitro" models Source: Annual Congress 2011 - T-cell subsets Year: 2011 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 The role anti-inflammatory cytokines in pathogenesis professional occupetional pulmonary disease Source: Eur Respir J 2003; 22: Suppl. 45, 122s Year: 2003 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 GM-CSF is a key pathogenic mediator in experimental COPD Source: Eur Respir J 2005; 26: Suppl. 49, 13s Year: 2005 The potential mechanism of Th17/Treg imbalance in the microenvironments of chronic inflammation and allergic asthma Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 Airway inflammation in asthma: current and future targets and therapies Source: Breathe 2010; 6: 245-252 Year: 2010 Macrolides targeting multiple immune pathways in asthma and COPD Source: Virtual Congress 2021 – Pharmacology of lung immune responses: which pathways to target! Year: 2021 Photobiomodulation acting as an immunotherapeutic strategy for chronic obstructive diseases such as asthma and COPD Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020 The proinflammatory cytokine is important in determining the severity of asthma enhancing the inflammatory process Source: Eur Respir J 2004; 24: Suppl. 48, 592s Year: 2004 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016